Clinical trial · Observational
Mechanisms of Immunosurveillance for Lung Cancer
NCT01710319CI-TRIAL-00032799MechLungCacompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to investigate the differences in "natural killer (NK) blood cells, a type of white blood cell that fights infection in the body, among different types of patients that have lung surgery. The four different groups of patients are: * smokers with lung cancer * smokers without lung cancer * non-smokers with lung cancer * non-smokers without lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood draw | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- smoker with lung cancer
- description
- patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and have lung cancer
- interventionNames
- Other: blood draw
- label
- smoker without lung cancer
- description
- patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and do not have lung cancer
- interventionNames
- Other: blood draw
- label
- nonsmoker with lung cancer
- description
- patients that have smoked less than 100 cigarettes in their lifetime and have lung cancer
- interventionNames
- Other: blood draw
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age equal or greater to 18 years * Ability to read and write in English * Able to participate in the informed consent process Exclusion Criteria: * Known active hepatitis B, hepatitis C, or HIV/AIDs (found in medical record) * Chemotherapy or radiation therapy within 3 months of enrollment * Type 1 Diabetes Mellitus * Rheumatoid arthritis, Lupus, Multiple Sclerosis, or any other autoimmune disease as deemed necessary for exclusion by the Principal Investigator * Previous organ transplant * Blood transfusion within 3 months prior to enrollment * Any previous cancer, excluding a previous lung cancer * Steroid use within 4 weeks of enrollment
References
Publications (3)
- BACKGROUNDBach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh LJ, Begg CB. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003 Mar 19;95(6):470-8. doi: 10.1093/jnci/95.6.470. PMID 12644540
- BACKGROUNDBondy SJ, Victor JC, Diemert LM. Origin and use of the 100 cigarette criterion in tobacco surveys. Tob Control. 2009 Aug;18(4):317-23. doi: 10.1136/tc.2008.027276. Epub 2009 Jun 1. PMID 19491091
- BACKGROUNDMurala SS, Gelman AE, Kreisel D, Krupnick AS. Natural killer cells play a critical role in immunosurveillance for murine lung cancer. American Surgical Congress, Proceedings in The Journal of Surgical Research 2011; 165: 292-293.